Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank

Study limitation reported by the research below: “The 'impact flag' of practice changing reflects the normative/guideline nature of the consensus rather than a clinical trial demonstrating superiority of a treatment.”